Price Alert

ARS Pharmaceuticals Inc. (SPRY)

NASDAQ: SPRY · Real-Time Price · USD

9.76

0.22 (2.31%)

At close: Sep 26, 2025, 3:13 PM

ARS Pharmaceuticals Statistics

Share Statistics

ARS Pharmaceuticals has 97.69M shares outstanding. The number of shares has increased by null% in one year.

Shares Outstanding	97.69M
Shares Change (YoY)	n/a
Shares Change (QoQ)	n/a
Owned by Institutions (%)	77.78%
Shares Floating	n/a
Failed to Deliver (FTD) Shares	24,606
FTD / Avg. Volume	1.13%

Short Selling Information

The latest short interest is 21.04M, so 21.29% of the outstanding shares have been sold short.

Short Interest	21.04M
Short % of Shares Out	21.29%
Short % of Float	34.69%
Short Ratio (days to cover)	8.09

Valuation Ratios

The PE ratio is 127.87 and the forward PE ratio is -11.89. ARS Pharmaceuticals's PEG ratio is -1.12.

PE Ratio	127.87
Forward PE	-11.89
PS Ratio	11.47
Forward PS	4.5
PB Ratio	3.98
P/FCF Ratio	78.76
PEG Ratio	-1.12

Financial Ratio History

Enterprise Valuation

ARS Pharmaceuticals has an Enterprise Value (EV) of 971.91M.

EV / Sales	10.9
EV / EBITDA	-338.05
EV / EBIT	71.74
EV / FCF	74.85

Financial Position

The company has a current ratio of 14.26, with a Debt / Equity ratio of 0.

Current Ratio	14.26
Quick Ratio	14.04
Debt / Equity	0
Debt / EBITDA	-0.01
Debt / FCF	n/a
Interest Coverage	0

Financial Efficiency

Return on Equity is 3.11% and Return on Invested Capital is -0.91%.

Return on Equity	3.11%
Return on Assets	2.28%
Return on Invested Capital	-0.91%
Revenue Per Employee	$575.15K
Profits Per Employee	$51.6K
Employee Count	155
Asset Turnover	0.25
Inventory Turnover	0.19

Taxes

Income Tax	288K
Effective Tax Rate	3.48%

Stock Price Statistics

The stock price has increased by -34.25% in the last 52 weeks. The beta is 0.92, so ARS Pharmaceuticals's price volatility has been higher than the market average.

Beta	0.92
52-Week Price Change	-34.25%
50-Day Moving Average	13.97
200-Day Moving Average	13.53
Relative Strength Index (RSI)	28.78
Average Volume (20 Days)	2,180,812

Income Statement

In the last 12 months, ARS Pharmaceuticals had revenue of 89.15M and earned 8M in profits. Earnings per share was 0.08.

Revenue	89.15M
Gross Profit	88.17M
Operating Income	-3.08M
Net Income	8M
EBITDA	-2.88M
EBIT	-3.08M
Earnings Per Share (EPS)	0.08

Full Income Statement

Balance Sheet

The company has 50.82M in cash and 42K in debt, giving a net cash position of 50.77M.

Cash & Cash Equivalents	50.82M
Total Debt	42K
Net Cash	50.77M
Retained Earnings	-123.31M
Total Assets	313.47M
Working Capital	235.84M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 13.55M and capital expenditures -563K, giving a free cash flow of 12.98M.

Operating Cash Flow	13.55M
Capital Expenditures	-563K
Free Cash Flow	12.98M
FCF Per Share	0.13

Full Cash Flow Statement

Margins

Gross margin is 98.9%, with operating and profit margins of -3.46% and 8.97%.

Gross Margin	98.9%
Operating Margin	-3.46%
Pretax Margin	9.29%
Profit Margin	8.97%
EBITDA Margin	-3.22%
EBIT Margin	-3.46%
FCF Margin	14.57%

Dividends & Yields

SPRY does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Payout Ratio	n/a
Earnings Yield	0.78%
FCF Yield	1.27%

Dividend Details

Analyst Forecast

The average price target for SPRY is $29, which is 204% higher than the current price. The consensus rating is "Buy".

Price Target	$29
Price Target Difference	204%
Analyst Consensus	Buy
Analyst Count	5

Stock Forecasts

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	2.22
Graham Upside	-76.73%

Scores

Altman Z-Score	4.61
Piotroski F-Score	1